Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 3/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 6/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080089 | 0.88 | SSTR2 (0.44) | SSTR2SLC2A1KCNH2 | |
| SCHEMBL5744249 | 0.85 | KCNH2 (0.49) | SSTR2SLC2A1KCNH2 | |
| Hydrochloric Acid SCHEMBL5746922 | 0.85 | KCNH2 (0.48) | SSTR2SLC2A1KCNH2 | |
| SCHEMBL6080374 | 0.85 | SSTR2 (0.37) | SSTR2SLC2A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6079762 | 0.82 | CNR2 (0.45) | SLC2A1KCNH2CNR1 | |
| SCHEMBL3253090 | 0.76 | PTPN11 (0.34) | SSTR2SLC2A1KCNH2 | |
| SCHEMBL3253088 | 0.76 | PTPN11 (0.34) | SSTR2SLC2A1KCNH2 | |
| SCHEMBL3246504 | 0.76 | PTPN11 (0.34) | SSTR2SLC2A1KCNH2 | |
| SCHEMBL3246499 | 0.76 | PTPN11 (0.34) | SSTR2SLC2A1KCNH2 | |
| SCHEMBL5744944 | 0.76 | KCNH2 (0.46) | SSTR2SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | SSTR2 4859/4885SLC2A1 4409/4885PAK4 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.